Here's Why Alzamend Neuro Stock Is Shooting Higher Today

Here's Why Alzamend Neuro Stock Is Shooting Higher Today
·2 min read

Shares of Alzamend Neuro (NASDAQ: ALZN), a biotechnology company in the pre-clinical stage, started Friday's trading 44% higher. Investors were thrilled with the positive results of a mouse toxicology study with an experimental new Alzheimer's disease treatment called AL002. Alzheimer's disease (AD) affects more than 6 million Americans, and this number is on the rise.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting